Tests VERVE-102 gene editing to lower cholesterol in adults at heart disease risk
Tests VERVE-102 gene editing against placebo in adults with artery plaque or high risk.
Plain-language title generated from the registry record
Registry title: A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease
Key facts
- Where
- DeSoto, United StatesSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07839936, who can take part
Where in United States
- Epic Medical ResearchDeSoto, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Verve Therapeutics, Inc.
- Trial code
- NCT07839936EU 2026-525691-26-00
- Record updated
- 10 November 2026
- Original description
The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.Read full original descriptionShow less
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of VERVE-102, a One-Time Dose Gene Editing Medicine, in Adults With or at High Risk for Atherosclerotic Cardiovascular Disease (ASCVD) Who Require Additional Low-Density Lipoprotein-Cholesterol (LDL-C) Lowering
The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.
Inclusion: Established atherosclerotic cardiovascular disease (ASCVD) and/or at a high risk of ASCVD.
Exclusion: Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe; History of confirmed or suspected homozygous familial hypercholesterolemia (HoFH); Chronic liver disease.